ArticleInternational urology and nephrology2025
Unveiling the bladder's early response to acute glucosuria: first evidence from an animal study.
Article in International urology and nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWhile chronic damage to the lower urinary tract in diabetic patients is well-known, the specific effects of acute glucosuria on the bladder remain unclear. This study, being the first of its kind in the available literature, aims to exclusively investigate the early effects of acute glucosuria on bladder function and morphology, independent of the broader impacts of diabetes.
methodsWistar Albino rats were divided into four groups: CONTROL, Empagliflozin (EMPA), Diabetes Mellitus + Empagliflozin (DM + EMPA), and DM. Acute glucosuria was induced using empagliflozin in the EMPA and DM + EMPA groups. The effects on bladder function were assessed through contraction protocols using potassium chloride (KCl), cumulative acetylcholine (ACh) applications and electrical field stimulation studies (EFS). The bladder tissues were also examined histopathologically to evaluate morphological changes.
resultsIn the organ bath studies, a significant increase in the response to KCl was observed in the diabetic group receiving empagliflozin compared to others (p < 0.001). When examining the contraction responses to ACh, it was found that the diabetic group receiving empagliflozin exhibited significantly higher contraction responses (p < 0.001). In the EFS, no significant difference was found between the groups. The histopathological examinations revealed a significant muscularis propria hypertrophy in the groups receiving empagliflozin compared to the control group (p < 0.001).
conclusionsIn our study, we found that short-term treatment defined as 15 days with empagliflozin increased the receptor-independent contractile capacity of the bladders in diabetic rats and enhanced their contraction responses to ACh. However, there was no significant difference observed in the EFS studies. Histopathological analysis revealed the development of detrusor hypertrophy in rats receiving empagliflozin treatment.
Indexed as
Identifiers
40221564What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.